Skip to main content

Table 2 Failure Sites for non-type A Failures

From: Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow

Patient Local vs Regional Predominant Failure Type Primary Tumor Site Pathologic TN Stage Surgical margins Neck dissection status and laterality ECE Neck Irradiation Laterality DOI PNI LVI Chemotherapy CTV1 Dose (Gy/n. of Fracions) Failure Site
1 L B (peripheral high dose) gingiva T2 N0 -ve -ve Ipsilat -ve Ipsilat ≤1.5 cm +ve -ve No 60/30 Ipsilat RMT&Maxilla
2 L B (peripheral high dose) FOM T1N2c -ve +ve Bilat +ve Bilat >1.5 cm -ve -ve No 13/6b FOM
3 L C (central int. dose) RMT yT4ayN0 -ve -ve Ipsilat -ve Bilat ≤1.5 cm -ve U/S I + C 60/30 Ipsilat Masticator Space
4 L C (central int. dose) tongue T4aN2b -ve +ve Bilat -ve Bilat >1.5 cm -ve -ve No 60/30 FOM
5 L C (central int. dose) FOM T4aN1 -ve +ve Bilat -ve Bilat >1.5 cm -ve -ve No 60/30 BOT
6 L Aa RMT T4aN1 +ve +ve Ipsilat -ve Ipsilat >1.5 cm +ve -ve No 70/33 Flap recurrence + Ipsilat Parotid & Masticator Space
7 L D (peripheral int. dose) gingiva T4aN1 +ve +ve Ipsilat -ve Bilat ≤1.5 cm +ve +ve No 63/30 Ipsilat Masticator Space
8 L E (extraneous) FOM T1 N1 -ve +ve Bilat -ve Bilat ≤1.5 cm +ve +ve No 60/30 Mandibular gingiva
9 L E (extraneous) gingiva T4aN1 -ve +ve Ipsilat -ve Ipsilat ≤1.5 cm -ve -ve No 60/30 Contralat mandibular gingiva
10 L E (extraneous) gingiva T4aN2b close +ve Ipsilat -ve Ipsilat ≤1.5 cm +ve -ve C 60/30 Ipsilat masticator space
11 L E (extraneous) Buccal yT2yN0 -ve -ve Ipsilat -ve Ipsilat >1.5 cm -ve -ve I + C 60/30 Ipsilat perineural spread along V2&V3
12 LR C (central int. dose) tongue T1 N1 -ve +ve Ipsilat +ve Bilat ≤1.5 cm -ve -ve C 60/30 FOM&Contralat level IIa
13 LR C (central low dose) tongue T2 N0 -ve -ve Ipsilat -ve Bilat ≤1.5 cm -ve +ve C 64/30 Contralat tongue&level II
14 R C (central low dose) Hard palate T3 N0 -ve -ve Ipsilat -ve Bilat ≤1.5 cm -ve -ve No 60/30 Contralat level IIa
15 R C (central low dose) gingiva T4aNx -ve No dissection N/A Ipsilat ≤1.5 cm -ve -ve No 64/32 Ipsilat level Ib
16 R C (central int. dose) RMT T2 N1 -ve +ve Ipsilat -ve Ipsilat ≤1.5 cm -ve -ve No 60/30 Ipsilat level Ib
17 R C (central low dose) tongue T2 N1 -ve +ve Ipsilat -ve Bilat ≤1.5 cm -ve -ve No 60/30 Contralat level Ib
18 R C (central int. dose) tongue T1 N1 -ve +ve Ipsilat -ve Bilat ≤1.5 cm -ve -ve No 56/28 Level Ia
19 R Aa tongue T3N2b -ve +ve Ipsilat +ve Bilat >1.5 cm +ve +ve C 60/30 Ipsilat level III (A) Contralat level IIa (C)
20 R Aa RMT T4aN2b close +ve Ipsilat -ve Bilat ≤1.5 cm -ve U/S C 60/30 Ipsilat level IIb (A) Ipsilat retropharyngeal node (D)
21 R E (extraneous) Buccal yT3yN0 close -ve Ipsilat -ve Ipsilat ≤1.5 cm +ve -ve I 60/30 Contralat Pterygoid plates& maxilla
22 R E (extraneous) Buccal T2N2b close +ve Ipsilat -ve Ipsilat ≤1.5 cm -ve +ve No 60/30 Ipsilat parotid node
23 R E (extraneous) Buccal T2N2b -ve +ve Ipsilat +ve Ipsilat ≤1.5 cm -ve -ve C 60/30 Ipsilat parotid node
24 R E (extraneous) Buccal T1N2b close +ve Ipsilat +ve Ipsilat U/S -ve U/S C 63/30 Contralat levels II, III, IV
25 R E (extraneous) gingiva T2Nx +ve No dissection N/A Ipsilat ≤1.5 cm -ve U/S No 65/30 Contralat level II
26 R G (low neck) tongue T1N2b -ve +ve Ipsilat -ve Bilat ≤1.5 cm +ve +ve No 60/30 contralat levels III, IV
27 R G (low neck) gingiva yT4ayN0 close -ve Ipsilat -ve Ipsilat >1.5 cm +ve U/S I 60/30 Ipsilat level VIb
  1. aIndicates type A failure with multifocal recurrence that includes non-type A lesions as well. bThis patient had received only 6 fractions and failed to appear for the remainder of her treatments. Abbreviations. ECE extracapsular extension, DOI depth of invasion, PNI perineural invasion, LVI lymphovascular invasion, L local, R regional, LR locoregional, FOM floor of mouth, RMT retromolar trigone, −ve negative, +ve positive, Ipsilat ipsilateral, Contralat contralateral, Bilat bilateral, U/S unspecified, I induction chemotherapy, C concurrent chemotherapy, I + C induction followed by concurrent chemotherapy, No no chemotherapy